Clinical trial NCT05409196 - References

Gastrointestinal Disease — Phase 1 Trial for Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Oral Shigella/ETEC Combination Vaccine to Healthy Adults

Citation(s)

•   Harutyunyan S, Neuhauser I, Mayer A, Aichinger M, Szijártó V, Nagy G, Nagy E, Girardi P, Malinoski FJ, Henics T
  Characterization of ShigETEC, a Novel Live Attenuated Combined Vaccine against Shigellae and ETEC. Vaccines (Basel). 2020 Nov 16;8(4). pii: E6

Phase 1 Two Stage Randomized, Double-blind, Placebo Controlled Dose- and Schedule Ranging Trial to Assess the Acute Safety, Tolerability, and Immunogenicity of a Live, Attenuated Shigella/ETEC Combination Vaccine Delivered Orally to Healthy Adults Age 18 to 45 Years Old

Details for clinical trial NCT05409196